Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Profit After Tax: 2010-2025

Historic Profit After Tax for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Profit After Tax rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 52.36%. This contributed to the annual value of $163.9 million for FY2024, which is 129.50% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Profit After Tax stood at $52.8 million for Q3 2025, which was up 1.30% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Profit After Tax ranged from a high of $56.7 million in Q1 2025 and a low of -$30.8 million during Q3 2023.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Profit After Tax value was $40.8 million (recorded in 2024), while the average stood at $36.1 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 235.24% in 2023, then soared by 242.65% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Profit After Tax (Quarterly) stood at $9.3 million in 2021, then soared by 173.62% to $25.5 million in 2022, then spiked by 36.80% to $34.8 million in 2023, then skyrocketed by 60.53% to $55.9 million in 2024, then increased by 20.28% to $52.8 million in 2025.
  • Its Profit After Tax stands at $52.8 million for Q3 2025, versus $52.1 million for Q2 2025 and $56.7 million for Q1 2025.